drugset / Trial / NCT01679002

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

NCT01679002

Phase 1 Completed 12 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the steady-state pharmacokinetics of once-daily and twice-daily regimens of BIA 2-093 and twice-daily regimen of Oxcarbazepine (Trileptal®) in healthy subjects and to assess the tolerability of such regimens in healthy subjects.

Timeline

Start
2003-10
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 450 mg Oral
Subject Eslicarbazepine acetate Unknown 900 mg Oral
Subject Oxcarbazepine Small molecule 450 mg Oral

Indications